The future of treatment for systemic lupus erythematosus.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  The Israel Medical Association journal : IMAJ

• Publication date

  2001-02-01

• Fields of study

  Medicine

• Identifiers
  PMID 11344823
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus

  2004cited by this paper
• Features of systemic lupus erythematosus in Dnase1-deficient mice

  2000cited by this paper
• Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II: Increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control.

  2000cited by this paper
• Antigen-specific therapy for autoimmune disease.

  2000cited by this paper
• The new prognosis of systemic lupus erythematosus: treatment-free remission and decreased mortality and morbidity.

  2000cited by this paper
• Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide

  2000cited by this paper
• Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity.

  2000cited by this paper
• Protection of Murine Lupus by the Ead Transgene Is MHC Haplotype-Dependent1

  2000cited by this paper
• Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus.

  2000cited by this paper
• Bromocriptine restores tolerance in estrogen-treated mice.

  2000cited by this paper
• CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus.

  2000cited by this paper
• Management of Murine Lupus by Correction of Fas and Fas Ligand-Induced Apoptosis

  1999cited by this paper
• Granulocyte-colony stimulating factor treatment of lupus autoimmune disease in MRL-lpr/lpr mice.

  1999cited by this paper
• Haematopoietic stem cell transplantation for active systemic lupus erythematosus.

  1999cited by this paper
• Suppression of systemic lupus erythematosus disease in mice by oral administration of kidney extract.

  1999cited by this paper
• Idiotypic vaccination with a murine anti-dsDNA antibody: phase I study in patients with nonactive systemic lupus erythematosus with nephritis.

  1999cited by this paper
• Lupus : molecular and cellular pathogenesis

  1999cited by this paper
• The role of clonal anergy in the avoidance of autoimmunity: inactivation of autocrine growth without loss of effector function

  1998cited by this paper
• Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study

  1998cited by this paper
• DNAse treatment does not improve the survival of lupus prone (NZB6NZW)F1 mice

  1998cited by this paper
• Stem cell transplantation for severe autoimmune disorders, with special reference to rheumatic diseases.

  1997cited by this paper
• Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels.

  1997cited by this paper
• The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone

  1996cited by this paper
• Remission of systematic lupus erythematosus.

  1996cited by this paper
• Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101.

  1996cited by this paper
• Remission of Systemic Lupus Erythematosus

  1996cited by this paper
• The penetration of autoantibodies into cells may induce tolerance to self by apoptosis of autoreactive lymphocytes and cause autoimmune disease by dysregulation and/or cell damage.

  1996cited by this paper
• Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus.

  1995cited by this paper
• Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus

  1995cited by this paper
• Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus.

  1993cited by this paper
• Binding of anti-DNA antibodies and inhibition of glomerulonephritis in MRL-lpr/lpr mice by heparin.

  1990cited by this paper
• Effect of the new immunoregulator AS-101 on in vitro functions of mononuclear cells from patients with systemic lupus erythematosus.

  1989cited by this paper

• Prolactin and Autoimmunity

  2012cites this paper
• Prolactin and autoimmunity.

  2012cites this paper
• Sex-based differences in regulatory T cells.

  2005cites this paper
• B cells underpin lupus immunopathology

  2002cites this paper
• Update: Treatment of systemic lupus erythematosus

  2002cites this paper
• The recovery of self tolerance in SLE

  2001cites this paper